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for 10% to 15% of disease burden. Allergy to cats is also a
major risk factor for the development of asthma.
Objectives: We sought to probe the persistence of the treatment
effect of a novel Fel d 1–derived peptide antigen desensitization
(Cat-PAD) 1 year after the start of treatment in subjects with
cat allergy–induced rhinoconjunctivitis after standardized
allergen challenge.
Methods: In a randomized, double-blind, placebo-controlled,
parallel-group clinical trial, subjects attended an environmental
exposure chamber in which they were exposed to cat allergen
before and after treatment with 2 different regimens of Cat-
PAD over a 3-month period. Clinical efficacy was assessed as a
change in total rhinoconjunctivitis symptom scores 18 to 22
weeks and 50 to 54 weeks after the start of treatment.
Results: Treatment with Cat-PAD showed greater efficacy with
4 administrations of a 6-nmol dose 4 weeks apart than with 8
administrations of a 3-nmol dose 2 weeks apart. The treatment
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was significantly different from that of 3 nmol (P 5 .0342) and
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and nasal components of rhinoconjunctivitis symptoms in
subjects with cat allergy, with the treatment effect persisting
1 year after the start of treatment. (J Allergy Clin Immunol
2013;131:103-9.)
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Allergic rhinitis is a common disorder, with prevalence ranging
from approximately 10% to 40% in adults and up to 40% in
children.1The reduction in quality of life and the economic effect of
allergic rhinitis are substantial.2 Of a population of 310million per-
sons in the United States, approximately 60million have allergies,3
and 17%of the population have positive skin prick test responses to
cat.4 Furthermore, sensitization to cat allergens is a potent risk
factor for the development of asthma; almost 30% of allergic
asthma in the United States is attributable to cat sensitization.5
The morbidity associated with allergic diseases disproportion-
ately affects socioeconomically disadvantaged populations, par-
ticularly children.6 Fel d 1 is detectable in many public places at
levels capable of sensitizing or exacerbating symptoms in suscep-
tible subjects, including children in schools.6
Peptide immunotherapy uses synthetic peptides consisting of
T-cell epitopes derived from major allergens and autoantigens to
induce antigen-specific tolerance. Delivery of T-cell epitopes
intradermally is thought to lead to the induction of T cells with a
regulatory phenotype, which results in downregulation of the
response to antigen.7 The identification of a set of T-cell epitopes
derived from Fel d 1 (Cat-peptide antigen desensitization [Cat-
PAD]) has been described previously.8
Evaluation of the efficacy of therapeutic interventions for
allergic rhinitis frequently relies on measurement of symptoms
with or without medication use in clinical trials in which
symptoms are elicited through natural exposure to allergen.
Although this methodology is believed to reflect ‘‘real-life’’
exposure, it is confounded by marked variability in levels of
allergen exposure. The use of an environmental exposure cham-
ber (EEC) allows for clinical trial subjects to be exposed to
aeroallergens in a highly controlled manner and allows the use of
pre-established allergen levels known to induce symptoms at the
moderate-to-severe level.9,10 In a previous unrelated pilot EEC
study we demonstrated that treatment with a 3-nmol dose of
Cat-PAD with 4 or 8 injections over a 12- or 14-week period re-
sulted in a greater reduction in mean total rhinoconjunctivitis
symptom scores (TRSSs) than placebo, with a mean treatment
difference of 2.9 units between 1 and 3 hours on days 2 and 4
of consecutive 3-hour EEC challenges 17 to 21 weeks after the
start of treatment.11103
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104 PATEL ET ALAbbreviations usedAE: Adverse eventEEC: Environmental exposure chamberPAD: Peptide antigen desensitizationPTC: Posttreatment challengeTEAE: Treatment-emergent adverse eventsTNSS: Total nasal symptom scoreTOSS: Total ocular symptom scoreTRSS: Total rhinoconjunctivitis symptom scoreThe purpose of the present study was to evaluate whether
efficacy could be further improved by administering the 6-nmol
dose of Cat-PAD (also known as ToleroMune Cat [Circassia
Limited, Oxford,UnitedKingdom]) 4 times over a 12-week period
(43 6 nmol) and to compare this regimenwith 83 3 nmol 2weeks
apart (83 3 nmol) and placebo. The studywas originally designed
with change in TRSSs measured 18 to 22 weeks after the start of
treatment. The data presented here summarize the results at 18 to
22 weeks and present a follow-up study in which subjects returned
to the EEC 1 year after the start of dosing and approximately
9months after the last dosingvisit,without any further retreatment.METHODS
Subjects
The study received prior ethical approval from Institutional Review Board
Services (Aurora, Ontario, Canada) and from Health Canada’s Biologics and
Genetic Therapies Directorate (the Canadian federal authority that regulates
biological drugs). The study was registered at www.clinicaltrials.gov (identi-
fiers: NCT01033344 and NCT01272323). Subjects were male or female (18-
65 years of age), had a history of rhinoconjunctivitis with or without Global
Initiative for Asthma step 1 asthma (http://www.ginasthma.com/) on exposure
to cats for at least 1 year, provided written informed consent, and were able to
comply with study requirements. Subjects with persistent asthma or subjects
using inhaled corticosteroids or leukotriene modifiers to manage their asthma
symptoms were excluded. Further details are provided in the Methods section
in this article’s Online Repository at www.jacionline.org.Clinical study design
This was a randomized, double-blind, placebo-controlled, parallel-group
study evaluating the safety and efficacy of intradermal injections of 2 dosing
regimens of Cat-PAD performed at the Cetero Research EEC in Mississauga,
Ontario, Canada. Subjects attended a screening visit and then a baseline
challenge of 4 consecutive days of 3 hours in the EEC, which occurred before
the first administration of study medication (see Fig E1 in this article’s Online
Repository at www.jacionline.org). Two hundred two subjects were random-
ized to one of 3 regimens (83 3 nmol 2 weeks apart, 43 6 nmol 4 weeks apart
with infill placebo to maintain blinding, or 8 3 placebo). Table E1 in this ar-
ticle’s Online Repository at www.jacionline.org provides further details of the
dosing regimens and treatment administration. After dosing, subjects returned
to the EEC for a further 4 consecutive days of 3-hour allergen exposures 18 to
22weeks after the start of treatment. Eighty-nine subjects were re-enrolled in a
follow-up study and returned to the EEC for a further 4 consecutive days of
3-hour allergen exposures at 50 to 54 weeks. Subjects and study staff remained
blind to treatment. A new principal investigator was appointed to maintain
blinding, and subjects were issued with new subject numbers to ensure blind-
ing of the Cetero, Adiga, and Circassia staff directly involved in the study. The
EEC is designed with clean-room technology using 100% fresh high-
efficiency particulate air filtering. Cat allergen was dispersed into the chamber
by an aerosol generator to achieve a consistent mean airborne level of 48.36
2.09 ng of Fel d 1/m3 using a fully validated method (Cetero Research). Each
participant was subjected to challenge at a consistent time throughout thestudy (eg, in the morning or afternoon) to minimize the effect of circadian
variations.Study medication
Cat-PAD is an equimolar mixture of 7 peptides, the sequences of which
(CPAVKRDVDLFLT, EQVAQYKALPVVLENA, KALPVVLENARILNCV,
RILKNCVDAKMTEEDKE, KENALSLLDKIYTSPL, TAMKKIQDCY
VENGLI, and SRVLDGLVMTTISSSK) are derived from Fel d 1, as
previously described.8 Study medication was supplied as a room tempera-
ture–stable lyophilisate of the 7 peptides or placebo and was reconstituted
with sterile diluent or water for injection by an unblinded pharmacist before
dosing. When reconstituted, the resulting solutions contained the 7 peptides
at 50 or 100 nmol/mL or placebo. The reconstituted placebo product
comprised the vehicle used to formulate the peptides. All subjects received
a 60-mL intradermal injection volume. The 3-nmol dose was equivalent to
approximately 37.5 mg of the 7 peptides.Primary efficacy measurement
The primary efficacy measurement was based on the TRSS. At all EEC
visits, subjects recorded symptoms in a diary just before entering the chamber
and at 30-minute intervals thereafter. Symptoms were divided into nasal
(running nose, sneezing, blocked nose, and itchy nose) and ocular (itchy eyes,
watery eyes, red eyes, and sore eyes) symptoms. For each symptom, the
subject rated the severity as follows: 0, absent; 1, mild and barely noticeable;
2, moderate and annoying/bothersome; and 3, severe and very annoying/very
bothersome. The TRSS was calculated by summing the nasal and ocular
symptom scores at each time point in the EEC. Subjects were required to have
a TRSS of at least 10 of 24 and a total nasal symptom score (TNSS) of at least 6
of 12 on at least 1 diary card on days 3 and 4 of baseline challenge. The
protocol-specified primary end point was the mean change in TRSSs at 50 to
54 weeks from 1 hour onward on days 2 to 4 of the posttreatment challenge
(PTC) compared with baseline values for nonasthmatic subjects. The primary
end point at 50 to 54 weeks was also analyzed in the total study population
(pooled asthmatic and nonasthmatic subjects).Secondary efficacy measurements
Secondary end points included the mean change from baseline values in
scores for ocular and nasal symptoms at time points after 1 hour on days 2 to 4
of PTC in the treatment groups compared with the placebo group and themean
change in TRSSs and nasal and ocular symptoms at all time points on all days.
An exploratory analysis of mean change from baseline concentrations of
cat-specific IgE at follow-up compared with that in the placebo groupwas also
performed.Safety measurements
Safety parameters included adverse events (AEs), physical examination
results, vital signs, clinical laboratory test results (hematology, blood
biochemistry, and urinalysis), spirometric results (FEV1), visual analog scale
scores of breathlessness and nasal symptoms, and local reactions at the injec-
tion site.AEs
At each visit, the investigator determined whether AEs had occurred by
asking nonleading questions. AE reporting began from obtaining signed
informed consent forms and ended after the follow-up visit.Statistical analysis
A comparison of each Cat-PAD dose with placebo was made by using an
analysis of covariance model with treatment as a factor and baseline
measurements as covariates. Statistical significance was accepted at a P value
of less than .05.
TABLE I. Change from baseline values in TRSSs at 1 to 3 hours
on days 2 to 4 after PTC at 18 to 22 and 50 to 54 weeks (primary
efficacy analysis nonasthmatic population)
Population No. Mean SD Median
TRSS change from baseline to PTC at 18-22 wk
Placebo 29 22.786 5.283 23.067
8 3 3 nmol 23 25.136 5.137 24.067
4 3 6 nmol 21 25.406 5.795 25.733
TRSS change from baseline to PTC at 50-54 wk
Placebo 29 22.908 5.558 23.267
8 3 3 nmol 23 23.893 5.559 23.733
4 3 6 nmol 21 26.778 5.711 26.800
TRSS difference between active and placebo groups
at 50-54 wk
LS means LS means 95% CI P value
Placebo 22.997 0 0 NA
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Study participants
Two hundred two subjects received at least 1 dose of study
medication and were included in the safety population. One
hundred seventy-four subjects completed at least 1 PTC visit to
the EEC and were included in the intention-to-treat analysis at 18
to 22 weeks (170 subjects with EEC data on days 2-4 of the PTC
were analyzed).Missing data were not replaced. All subjects were
invited to participate in a 1-year follow-up study. Ninety agreed,
and after 1 screening failure, 89 subjects were enrolled in the
blinded 1-year follow-up study detailed here and attended at least
1 EEC visit 1 year after the start of Cat-PAD. Demographic details
(see Table E2 in this article’s Online Repository at www.
jacionline.org), disposition of subjects, and numbers analyzed
(see Fig E2 in this article’s Online Repository at www.
jacionline.org) are presented in this article’s Online Repository.8 3 3 nmol 23.509 20.512 23.539 to 2.515 .7369
4 3 6 nmol 27.074 24.077 27.165 to 20.989 .0104
TRSS difference between active treatments
4 3 6 nmol vs 8 3 3 nmol 23.565 26.856 to 20.274 .0342
Least squares means, 95% CIs, and P values are based on an analysis of covariance,
with change from baseline as the dependent variable, treatment as the fixed effect, and
baseline as the covariate. P values are from a 2-sided test at the 5% level.
LS means, Least squares means; NA, not applicable.Primary efficacy variable
A summary of the change from baseline in mean TRSSs for the
nonasthmatic subjects participating in the 1-year follow-up study
after the start of treatment can be found in Table I; data for the
same subjects at the 18- to 22-week visit to the EEC are also
shown. For the nonasthmatic population, the results demonstrated
a decrease in mean TRSSs from baseline (ie, a greater decrease in
symptom severity) for 6 nmol (26.778)when comparedwith both
3 nmol (23.893) and placebo (22.908). Median values showed
the same trend. The change in TRSSs observed with 6 nmol
was significantly different than the changes observed with
3 nmol (P 5 .0342) and placebo (P 5 .0104).
The treatment effect at 18 to 22 weeks in subjects who attended
the 1-year follow-up study showed a greater mean change from
baseline TRSSs (ie, a greater decrease in symptom severity) for
both 6 nmol (25.406) and 3 nmol (25.136) when compared with
placebo (22.786). Median values showed the same trend.
Comparison of the 50- to 54-week visit versus the 18- to 22-
week visit showed the treatment effect (difference between active
and placebo treatment) might have increased for 6 nmol. The
treatment effects seen at 18 to 22 weeks in subjects who
participated in the 1-year follow-up study were similar to those
seen at 18 to 22 weeks in the full study population (mean change
in TRSS: 6 nmol 5 25.556, 3 nmol 5 24.870, and placebo 5
23.524). This demonstrates the subjects who participated in the
1-year follow-up study were representative of the main study
population.
Fig 1, A, shows mean TRSSs at each time point on each day for
the EEC visits at baseline challenge. A modest priming effect of
sequential allergen exposure was observed, with an approximate
peak TRSS of 14 on day 1 and increasing to 16 on day 4. A brisker
response to allergen exposure was also observed with time. On
day 1, a 1-hour exposure elicited a TRSS of approximately 9,
whereas on day 4, a score of greater than 12 was achieved.
Fig 1, B, shows mean TRSSs at each time point on each day for
the EEC visits at 18 to 22weeks, and Fig 1,C, showsmean TRSSs
at each time point on each day for the EECvisits at 50 to 54weeks.
It is noteworthy that on day 4 of the EEC challenge, TRSSs de-
creased from a plateau of approximately 16 at the end of the base-
line challenge to less than 7 during the 1-year follow-up visit for
subjects receiving 6 nmol of Cat-PAD.
Fig 2 shows the mean difference in TRSSs between the
baseline challenge and the 1-year follow-up visit for 6 nmoland placebo. The 6-nmol regimen shows a mean treatment effect
of approximately 5 TRSS units more than placebo at the end of
day 4 during the 1-year follow-up visit.Secondary efficacy variables
Analysis of changes in TRSSs at 1 year for the pooled
asthmatic and nonasthmatic subjects (total population) was
performed for sensitivity testing (Table II). The results showed
a larger decrease in mean change from baseline TRSSs (ie, a
greater decrease in symptom severity) for 6 nmol (26.353)
when compared with 3 nmol (23.636) and placebo (22.488).
Median values showed the same trend. The change in TRSSs ob-
served with 6 nmol was significantly different from that observed
with 3 nmol (P 5 .0311) and placebo (P 5 .0057). The small
number of asthmatic subjects did not permit a separate statistical
analysis for the effect of peptide immunotherapy in this category
of patients.
A summary of the changes in TNSSs and total ocular symptom
scores (TOSSs) for the nonasthmatic population at 50 to 54 weeks
can be found in Tables III and IV, respectively. The results showed
a larger decrease in mean change from baseline TNSSs (ie, a
greater decrease in symptom severity) for 6 nmol (23.435)
when compared with both 3 nmol (22.177) and placebo
(21.625). Median values showed the same trend. The change in
TNSSs observed with 6 nmol was significantly different from
that seen with placebo (P 5 .0200). The results also showed a
larger decrease inmean change from baseline TOSSs (ie, a greater
decrease in symptom severity) for 6 nmol (23.343) when com-
pared with both 3 nmol (21.716) and placebo (21.283). Median
values showed the same trend. The change in TOSSs observed
with 6 nmol was significantly different from that observed with
3 nmol (P 5 .0292) and placebo (P 5 .0121).
An exploratory analysis of changes in cat-specific IgE levels
demonstrated no obvious or significant changes after the 1-year
AB
C
FIG 1. TRSSs (means 6 SEMs) at each 30-minute time point (3 hours per day) in the chamber over 4
consecutive days: score at baseline (A), score at 18 to 22 weeks after the start of treatment (B), and score at
challenge 50 to 54 weeks after the start of treatment (C).
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with the baseline EEC visit or the visit to the EEC at 18 to
22 weeks (see Table E3 in this article’s Online Repository at
www.jacionline.org).Safety
Table V summarizes treatment-emergent adverse events
(TEAEs) by treatment arm in the safety population (all subjects
receiving >_1 dose) for the initial study. Table E4 in this article’s
Online Repository at www.jacionline.org summarizes the
TEAE frequency by using the Medical Dictionary for Regulatory
Activities System Organ Class and treatment group. There were
no deaths reported during this study. There was 1 serious AE, a
skin laceration, in a subject in the placebo group, which was
judged to be of moderate severity and not related to the studydrug. There were no serious AEs in the asthmatic population re-
lating to their asthma.
A total of 267 TEAEs were reported: 84 TEAEs were reported
by 44 different subjects after receiving placebo, 103 TEAEs were
reported by 48 different subjects after receiving 3 nmol, and 80
TEAEs were reported by 36 different subjects after receiving
6 nmol. Therewas no evidence that the higher-dose regimen led to
more TEAEs.
The majority of recorded TEAEs were mild in severity, with no
TEAEs rated as severe. Six subjects did not complete the study
because of a TEAE (placebo: 1 subject with back pain; Cat-PAD
3 nmol: 1 subject with arthralgia and pain in extremities and 2
subjects with bronchospasm; and Cat-PAD 6 nmol: 1 subject with
hypersensitivity and 1 subject with presyncope and convulsion).
The majority of TEAEs, including 5 of the 6 AEs leading to
withdrawal, were assessed as unrelated to the study drug. The
FIG 2. Difference in TRSSs (means 6 SEMs) at each 30-minute time point (3 hours per day) in the chamber
over 4 consecutive days: score at baseline challenge minus score at PTC 50 to 54 weeks after start of
treatment.
TABLE II. Secondary efficacy analysis: change from baseline in
TRSSs at 1 to 3 hours on days 2 to 4 after PTC at 18 to 22 and 50
to 54 weeks (pooled asthmatic and nonasthmatic population)
Population No. Mean SD Median
TRSS change from baseline to PTC at 18-22 wk
Placebo 36 23.096 4.984 23.600
8 3 3 nmol 28 24.610 5.136 24.100
4 3 6 nmol 24 24.992 5.679 25.200
TRSS change from baseline to PTC at 50-54 wk
Placebo 36 22.488 5.385 23.200
8 3 3 nmol 28 23.636 5.136 23.300
4 3 6 nmol 24 26.353 5.748 26.033
TRSS difference between active and placebo groups
at 50-54 wk
LS means LS means 95% CI P value
Placebo 22.629 0 0 NA
8 3 3 nmol 23.322 20.693 23.313 to 1.926 .600
4 3 6 nmol 26.507 23.878 26.598 to 21.158 .0057
TRSS difference between active treatments
4 3 6 nmol vs 8 3 3 nmol 23.185 26.074 to 20.296 .0311
Least squares means, 95% CIs, and P values are based on an analysis of covariance,
with change from baseline as the dependent variable, treatment as the fixed effect, and
baseline as the covariate. P values are from a 2-sided test at the 5% level.
LS means, Least square means; NA, not applicable.
TABLE III. Secondary efficacy analysis: change from baseline in
TNSSs at 1 to 3 hours on days 2 to 4 after PTC at 18 to 22 and 50
to 54 weeks (nonasthmatic population)
Population No. Mean SD Median
TNSS change from baseline to PTC at 18-22 wk
Placebo 29 21.515 2.811 21.067
8 3 3 nmol 23 22.452 2.404 22.200
4 3 6 nmol 21 22.838 3.015 22.800
TNSS change from baseline to PTC at 50-54 wk
Placebo 29 21.625 2.953 21.400
8 3 3 nmol 23 22.177 2.758 22.000
4 3 6 nmol 21 23.435 3.047 22.667
TNSS difference between active and placebo groups
at 50-54 wk
LS means LS means 95% CI P value
Placebo 21.649 0 0 NA
8 3 3 nmol 21.988 20.339 21.945 to 1.268 .6753
4 3 6 nmol 23.609 21.960 23.601 to 20.319 .0200
TNSS difference between active treatments
4 3 6 nmol vs 8 3 3 nmol 21.621 23.380 to 0.138 .0702
Least squares means, 95% CIs, and P values are based on an analysis of covariance,
with change from baseline as the dependent variable, treatment as the fixed effect, and
baseline as the covariate. P values are from a 2-sided test at the 5% level.
LS means, Least squares means; NA, not applicable.
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assessed as related to the study drug.
There were no clinically significant findings related to any
clinical laboratory evaluation. No reductions in FEV1 of greater
than 30% (prospectively defined cutoff) were observed in any
treatment group at any treatment visit. The majority of
injection-site inspections were assessed as normal, and no abnor-
mal assessment was considered clinically significant. Visual ana-
log scale scores of breathlessness and nasal symptoms remained
low in the 1 hour after dosing for the active treatment regimens
and placebo on all dosing days.
Analysis of the respiratory system TEAEs shows no evidence
of any safety signal. Three subjects receiving 6 nmol experienced
an episode of dyspnea, bronchospasm, or asthma, whereas 14subjects receiving 3 nmol and 11 subjects receiving placebo
reported such an episode. The majority of these events occurred
during the PTC in the EEC at 18 to 22 weeks.DISCUSSION
We have previously identified 7 synthetic peptides that contain
the major T-cell epitopes from the cat allergen Fel d 1.8 The pro-
liferative and cytokine responses to these 7 peptides when admin-
istered together were equivalent to those observed with whole cat
dander extract. Unlike whole cat dander extract, however, the
7 peptides did not induce histamine release in blood basophils.
A previous proof-of-concept study conducted in the
EEC demonstrated that either 4 or 8 administrations of 3 nmol
TABLE V. TEAEs in the safety population (subjects receiving
>_1 dose of Cat-PAD or placebo)
TEAEs
Placebo
(N 5 69)
8 3 3 nmol
(N 5 67)
4 3 6 nmol
(N 5 66)
No. (%) E No. (%) E No. (%) E
All TEAEs 44 (63.8%) 84 48 (71.6%) 103 36 (54.5%) 80
Serious TEAEs 1 (1.4%) 1 0 (0.0%) 0 0 (0.0%) 0
TEAEs leading to
withdrawal
1 (1.4%) 1 3 (4.5%) 4 2 (3.0%) 4
TEAEs considered related
to study drug by
principal investigator
13 (18.8%) 18 18 (26.9%) 25 14 (21.2%) 20
E, Total number of TEAEs; N, number of subjects exposed; No., number of subjects
exposed who experienced 1 or more TEAEs; %, percentage based on N.
TABLE IV. Secondary efficacy analysis: change from baseline in
TOSSs at 1 to 3 hours on days 2 to 4 after PTC at 18 to 22 and 50
to 54 weeks (nonasthmatic population)
Population No. Mean SD Median
TOSS change from baseline to PTC at 18-22 wk
Placebo 29 21.271 3.000 21.200
8 3 3 nmol 23 22.684 3.052 21.867
4 3 6 nmol 21 22.568 3.123 21.867
TOSS change from baseline to PTC at 50-54 wk
Placebo 29 21.283 2.923 21.267
8 3 3 nmol 23 21.716 3.169 21.467
4 3 6 nmol 21 23.343 3.048 23.000
TOSS difference between active and placebo groups
at 50-54 wk
LS means LS means 95% CI P value
Placebo 21.353 0 0 NA
8 3 3 nmol 21.531 20.179 21.767 to 1.409 .8231
4 3 6 nmol 23.448 22.096 23.718 to 20.473 .0121
TOSS difference between active treatments
4 3 6 nmol vs 8 3 3 nmol 21.115 22.464 to 0.235 .0292
Least squares means, 95% CIs, and P values are based on an analysis of covariance,
with change from baseline as the dependent variable, treatment as the fixed effect, and
baseline as the covariate. P values are from a 2-sided test at the 5% level.
LS means, Least squares means; NA, not applicable.
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changes in TRSSs than placebo 17 to 21 weeks after the start of
treatment.11 One of the purposes of this study was to evaluate the
persistence of clinical efficacy 1 year after the start of treatment
with 4 administrations of 6 nmol of Cat-PAD over a 12-week pe-
riod or with 8 administrations of 3 nmol of Cat-PAD over a 14-
week period compared with placebo.
The use of precisely standardized pretreatment and posttreat-
ment allergen challenges in an EEC allowed the accurate deter-
mination of efficacy, including the onset of action, magnitude, and
duration of the treatment effect. The mean level of Fel d 1 in the
EEC in the present study of 48 ng/m3was within the range of 10 to
200 ng/m3 reported for airborne Fel d 1 levels in homes with
cats.12 Previously, studies of allergen immunotherapy have not
systematically evaluated the effect of dose and dosing regimen
on the persistence of a treatment effect after withdrawal of ther-
apy. In the current study the strongest treatment effect in the
1-year follow-up was observed in the group treated with 6 nmol
of Cat-PAD. This group showed statistically significantdifferences in mean TRSSs versus treatment with placebo and
3 nmol of Cat-PAD, as well as the component scores, TNSS
and TOSS, versus placebo.
As exemplified in Fig 2, there is a substantial reduction in mean
TRSSs in the nonasthmatic population between subjects who re-
ceived 6 nmol of Cat-PAD and those who received placebo. At
time points from 1 hour onward on days 2 to 4 in the EEC, the
mean difference between placebo and 6 nmol was 3.9 units on
the TRSS scale.
Although the same cumulative antigen dose (24 nmol) was
administered with both regimens and a treatment effect was
seen at 18 to 22 weeks for both, the reduction in rhinocon-
junctivitis symptoms persisted to a much greater extent at the
1-year follow-up for the 6-nmol dose compared with the 3-nmol
dose. We speculate that a threshold immunologic event was
triggered with the 6-nmol dose, resulting in the maintained
effect. Further studies are needed to evaluate the long-term
immunomodulatory changes arising as a result of peptide
immunotherapy, as well as the immunologic effect of the
different dosing regimens, to understand the nature of this
threshold immunologic event.
Previous studies have demonstrated reduced allergen-specific
proliferation and TH2 cytokine responses in PBMCs after peptide
immunotherapy.13,14 In contrast, IL-10 production was increased
and, in a murine model of peptide immunotherapy for cat allergy,
played a central role in immunologic tolerance to the allergen.15
Peptide treatment was associated with upregulation of CD5, a
molecule involved in T-cell activation and division, perhaps lim-
iting T-cell expansion.16 It has also been demonstrated that the
tolerogenic environment created by treatment with a limited num-
ber of peptides can result in limited local tolerance to other T-cell
epitopes within the same allergen.15
The TRSS used in this study has been used as a subjective
outcome measure in numerous clinical trials of pharmacotherapy
and allergen immunotherapy.17-19 The observed change of 3.9
TRSS units in the current study represents a substantial improve-
ment over current approaches because these approaches have
been evaluated in a similar system (ie, in studies using TRSS out-
comes with an EEC design). For example, studies of similar
design reported TRSS changes of approximately 2 units for adju-
vanted subcutaneous immunotherapy20 and daily sublingual grass
immunotherapy,21 whereas a single 180-mg dose of the antihista-
mine fexofenadine achieved a mean difference in TRSSs of 1.3.22
Moreover, the change in TRSSs reported here was observed after
just 4 administrations of Cat-PAD and persisted 9 months after
treatment cessation.
In conclusion, the optimal dose and dosing regimen of Cat-
PAD has been identified as 4 administrations of a 6-nmol dose
4 weeks apart, and a persistent improvement in rhinoconjuncti-
vitis symptoms lasting at least 1 year after the start of treatment
has been demonstrated.
Clinical implications: Short-course (4 administrations) immu-
notherapy with T-cell epitopes significantly improves clinical
symptoms of cat allergen–induced rhinoconjunctivitis 1 year af-
ter the start of treatment.REFERENCES
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Clinical characteristics of subjects in the clinical
study
Male or female subjects aged 18 to 65 years were required to have a 1-year
documented history of cat allergen–induced rhinoconjunctivitis and a positive
skin prick test response to cat allergen with a wheal diameter at least 3 mm
larger than that produced by the negative control. Female subjects of
childbearing potential were required to practice an acceptable form of
contraception. Subjects must have achieved minimum qualifying symptom
scores on at least 1 symptom diary card during EEC exposure on the third and
fourth days during the baseline challenge. Minimum qualifying symptom
scores were defined as a TRSS of at least 10 of a possible 24 and a TNSS of at
least 6 of a possible 12, and the subject must have been willing and able to
comply with the study requirements.
Subjects were excluded from the study if they had persistent asthma falling
under the Global Initiative for Asthma classifications ‘‘partly controlled’’ and
‘‘uncontrolled,’’ an FEV1 of less than 70% of normal value, or a history of an-
aphylaxis to cat allergen or received allergen immunotherapy in the last
12 months or cat dander immunotherapy ever. Subjects with seasonal allergic
rhinoconjunctivitis who could not complete the clinical study outside the rel-
evant pollen season, who had significant allergy to other animal dander that
could not be avoided during the study period, or who were unable to tolerate
the baseline challengewere also excluded. Furthermore, subjects were not per-
mitted to use corticosteroids, cromones, antihistamines other than loratadine,
leukotriene inhibitors, anticholinergic agents, a-adrenergic agonists, tricyclic
antidepressants, monoamine oxidase inhibitors, b-blockers, a-adrenoceptor
blockers, tranquilizers, or psychoactive drugs during the study. Additional ex-
clusion criteria included subjects for whom administration of epinephrine was
contraindicated (eg, subjectswith acute or chronic symptomatic coronary heart
disease or severe hypertension) and subjects being treated with b-blockers.
Additionally, subjects with symptoms of a clinically relevant illness within
6 weeks before the screening visit and subjects with clinically relevant abnor-
malities detected on physical examinationvital signs, or laboratory values out-
side the normal ranges were excluded. Female subjects who were pregnant,
lactating, or planning a pregnancyduring the studywere also excluded. Finally,
subjects were also excluded if they had a significant history of alcohol or drug
abuse or a history of immunopathologic diseases; had previously been random-
ized into this study or had receivedCat-PADpreviously; had a history of severe
drug allergy, severe angioedema, or an anaphylactic reaction to food; had re-
ceived treatment with an investigational drug within 6 months before study
screening; were unable to communicate or understand the requirements of
the study; had any significant disease or disorder that, in the opinion of the in-
vestigator, might either have put the subject at risk because of participation in
the study or influenced the results of the study or the subject’s ability to partic-
ipate in the study; or had a known allergy to thioglycerol.Randomization
In the first part of the study, in which the treatments were administered,
subjects were randomly assigned to Cat-PAD (8 3 3 nmol), Cat-PAD (4 3 6
nmol), or placebo in a 1:1:1 ratio after the baseline challenge in the EEC.
Randomization was performed by using a computer-generated algorithm.
Subjects were randomized in blocks of 6. Randomization was stratified
according to whether the subjects had regular exposure to a cat and by
diagnosis of asthma. Cetero Research generated the random allocation
sequence. Blinded Cetero Research staff enrolled participants and assigned
participants to treatments according to the randomization schedule. In the
1-year follow-up that constitutes the main part of this article, all subjects from
the initial study were contacted, and 89 agreed to participate. No further
treatment was administered.
Study medication administration
Treatments were administered by means of intradermal injection into the
flexor surface of the left forearm every 2 weeks (62 days) for 14 weeks (Table
E1). The 8 3 3-nmol regimen consisted of 8 injections of 3 nmol, with each
injection separated by 2 weeks. The 43 6-nmol regimen consisted of 4 injec-
tions of 6 nmol, with each injection separated by 4 weeks. Placebo injections
were inserted into the dosing schedule for the 43 6-nmol regimen to maintain
blinding. The placebo arm consisted of 8 injections of placebo, with each in-
jection separated by 2 weeks. Previous studies have shown both Cat-PAD and
placebo lead to a mild erythema and wheal response after intradermal injec-
tion. Consequently, no additional actions were considered necessary to main-
tain blinding after product administration.
Study medication manufacture
The peptides were synthesized by Bachem (Bubendorf, Switzerland),
according to current Good Manufacturing Practice. The lyophilized Cat-PAD
product was formulated, filled, and finished by Patheon (Monza, Italy) and the
lyophilized placebowasmanufactured byAptuit (Glasgow, United Kingdom),
also according to current Good Manufacturing Practice. The materials were
tested at Patheon and Gen-Probe (Livingston, United Kingdom) and released
in accordancewith the European Union (Directive 2001/20/EC) and Canadian
(Food and Drug Act, Section C.05.010) regulations after labeling and
packaging at Aptuit (Bathgate, United Kingdom).
Recruitment
For the initial study, the first subject was screened on December 7, 2009,
and the last subject completed on October 6, 2010. For the 1-year follow-up,
the first subject was screened on February 7, 2011, and the last subject
completed on April 28, 2011. In both cases the trial ended after successful
completion of the last subject.
A500PC500PC
Period 1 Period 2 Period 3   Screening EEC Challenge/Follow-Up Screening/Baseline Challenge Treatment PTC/Follow-Up   
    Randomisation                      
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      (n = 28) 
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                     X - - - - - - - - - - -  X      
                       EEC Challenge   
            PTC               X- - - - - - - - - - -X   
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FIG E1. Overall study design. The baseline challenge and PTC both consisted of 3 hours in the EEC exposed
to cat allergen on 4 consecutive days. Two dosing regimens of Cat-PAD were compared with placebo:
Cat-PAD (1), 8 3 3 nmol administered 2 weeks apart; Cat-PAD (2), 4 3 6 nmol administered 4 weeks apart.
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FIG E2. Disposition of subjects and populations for analysis. *One subject in the 4 3 6-nmol regimen
included in the nonasthmatic populationwithdrew after PTC at weeks 50 to 54 on day 1 and therefore had no
data for the analysis, which used data from days 2 to 4.
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TABLE E1. Treatment regimens and treatment schedule for
Cat-PAD
Visit 3A 3B 3C 3D 3E 3F 3G 3H
Week 0 2 4 6 8 10 12 14
Regimen
8 3 3 nmol X X X X X X X X
4 3 6 nmol X P X P X P X P
Placebo P P P P P P P P
P, Placebo administration; X, Cat-PAD administration.
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TABLE E2. Demographic data of subjects participating in the
1-year follow-up study
Characteristic
Placebo
(n 5 36)
8 3 3 nmol
(n 5 28)
4 3 6 nmol
(n 5 25)
Race, no. (%)
American Indian/Alaska Native 0 (0.0) 0 (0.0) 1 (4.0)
Asian 2 (5.6) 1 (3.6) 2 (8.0)
Black/African American 4 (11.1) 4 (14.3) 0 (0.0)
Mixed 3 (8.3) 0 (0.0) 2 (8.0)
White 27 (75.0) 23 (82.1) 20 (80.0)
Ethnicity, no. (%)
Hispanic or Latino 5 (13.9) 1 (3.6) 5 (20.0)
Not Hispanic or Latino 31 (86.1) 27 (96.4) 20 (80.0)
Sex, no. (%)
Male 21 (58.3) 9 (32.1) 15 (60.0)
Female 15 (41.7) 19 (67.9) 10 (40.0)
Age (y)
Mean 6 SD 38.0 6 11.2 39.5 6 11.6 35.9 6 9.1
Range 19-62 21-65 22-56
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TABLE E3. Exploratory efficacy analysis: change from baseline in cat-specific IgE levels (kIU/L) after PTC at 18 to 22 and 50 to 54 weeks
Parameter
Treatment group
Placebo 8 3 3 nmol 4 3 6 nmol
No. of subjects 29 23 22
Mean 6 SD cat-specific IgE level at screening visit 6.651 6 8.602 22.048 6 39.303 11.951 6 19.955
Median cat-specific IgE at screening visit 3.050 3.960 4.080
Mean 6 SD cat-specific IgE after EEC challenge at 18-22 wk 9.180 6 11.958 21.564 6 32.919 12.122 6 17.569
Median cat-specific IgE level after EEC challenge at 18-22 wk 3.810 6.910 6.640
Mean 6 SD cat-specific IgE level after EEC challenge at 50-54 wk 8.234 6 10.771 18.546 6 26.986 10.555 6 17.960
Median cat-specific IgE level after EEC challenge at 50-54 wk 3.500 6.850 4.565
No significant changes were found for any of the treatment regimens.
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TABLE E4. TEAE frequency by System Organ Class and treatment group after administration of Cat-PAD or placebo
System Organ Class Preferred Term
Treatment group
Placebo (n 5 69) 8 3 3 nmol (n 5 67) 4 3 6 nmol (n 5 66)
Subject with >_1 AE 44 (63.8%) 48 (71.6%) 36 (54.5%)
Nervous system disorders 23 (33.3%) 15 (22.4%) 15 (22.7%)
Respiratory, thoracic, and mediastinal disorders 20 (29.0%) 18 (26.9%) 13 (19.7%)
Infections and infestations 9 (13.0%) 16 (23.9%) 12 (18.2%)
Skin and subcutaneous tissue disorders 4 (5.8%) 7 (10.4%) 2 (3.0%)
Immune system disorders 2 (2.9%) 4 (6.0%) 5 (7.6%)
Injury, poisoning, and procedural complications 4 (5.8%) 3 (4.5%) 4 (6.1%)
Musculoskeletal and connective tissue disorders 2 (2.9%) 4 (6.0%) 5 (7.6%)
Eye disorders 2 (2.9%) 5 (7.5%) 0 (0.0%)
Gastrointestinal disorders 3 (4.3%) 5 (7.5%) 2 (3.0%)
General disorders and administration site conditions 1 (1.4%) 2 (3.0%) 1 (1.5%)
Pregnancy, puerperium, and perinatal conditions 1 (1.4%) 0 (0.0%) 2 (3.0%)
Psychiatric disorders 0 (0.0%) 1 (1.5%) 0 (0.0%)
Renal and urinary disorders 0 (0.0%) 0 (0.0%) 1 (1.5%)
Reproductive system and breast disorders 0 (0.0%) 0 (0.0%) 1 (1.5%)
Vascular disorders 0 (0.0%) 1 (1.5%) 1 (1.5%)
Ear and labyrinth disorders 0 (0.0%) 1 (1.5%) 0 (0.0%)
Data are shown for 202 subjects randomized to treatment and cover the period to the close-out visit occurring 3 to 10 days after the EEC visit at 18 to 22 weeks. Counts reflect
numbers of subjects reporting 1 or more AEs that map to the Medical Dictionary for Regulatory Activities System Organ Class/Preferred Term. At each level of summarization
(System Organ Class or Preferred Term), subjects reporting more than 1 AE are counted only once.
n, Number of subjects exposed; %, percentage based on n.
J ALLERGY CLIN IMMUNOL
JANUARY 2013
109.e7 PATEL ET AL
